文献速递肿瘤 PET/CT

coPERCIST:AI辅助PET-CT疗效评估

coPERCIST: AI-assisted PET-CT response assessment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-22

本研究介绍集成于RECOMIA平台的AI辅助模块coPERCIST,可半自动完成PERCIST分析中的器官分割、背景活性量化、病灶检测、SULpeak计算及纵向病灶比较。在58例肿瘤患者共130个病灶中,AI建议的肝脏和主动脉阈值感兴趣区全部正确,解剖对齐全部准确,成对SULpeak量化准确率95%,多数病例复习时间不足1分钟。

要点

  • AI建议的肝脏和主动脉阈值感兴趣区在全部基线和随访研究中均正确。
  • 130个病灶解剖对齐全部准确,成对SULpeak量化准确率95%。
  • 多数病例复习时间不足1分钟。

核心结论

  • AI辅助PERCIST评估[18F]FDG PET-CT具有可行性且准确率良好,有望支持可重复的疗效评估并推动多中心验证。

研究设计与样本

  • coPERCIST为集成于RECOMIA平台的AI辅助模块,半自动执行PERCIST工作流关键步骤。
  • 研究纳入58例肿瘤患者,每例有两次PET-CT扫描,每人分析最多3个可测量病灶。

主要发现

  • AI建议的肝脏和主动脉阈值计算感兴趣区在全部基线和随访研究中均正确。
  • 随访研究分类为进展性代谢病(PMD)38例、稳定性代谢病(SMD)16例、部分代谢缓解(PMR)4例。
  • 130个评估病灶中解剖对齐全部准确,成对SULpeak量化准确率为95%。
  • 7对病灶的成对SULpeak量化失败,原因为邻近其他病灶或生理性摄取误分类。
  • 多数病例复习时间不足1分钟。

临床怎么用

  • coPERCIST可半自动完成PERCIST分析,并通过RECOMIA平台免费向研究者开放。

局限性

  • 研究为单中心可行性评估,尚需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The PET Response Criteria in Solid Tumours (PERCIST) 1.0 provides a standardized framework for evaluating treatment response using [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography - computed tomography (PET-CT), but its clinical use is hindered by manual complexity. This study presents coPERCIST, an artificial intelligence (AI)-assisted module integrated into the RECOMIA platform that semi-automates and streamlines PERCIST analysis. METHODS: coPERCIST performs organ segmentation and automates key steps of the PERCIST workflow, including background activity quantification, lesion detection, SULpeak calculation, and longitudinal lesion comparison. A novel image alignment method using organ-specific transformations and uncertainty estimation enables accurate lesion tracking over time. The system was evaluated in 58 oncological patients, each with two PET-CT scans. Up to three measurable lesions per patient were analysed. RESULTS: The AI-suggested liver and aorta volume of interest for threshold calculation were correct in all baseline and follow-up studies. Follow-up studies were classified as progressive metabolic disease (PMD) in 38 cases, stable metabolic disease (SMD) in 16, and partial metabolic response (PMR) in 4. Of 130 lesions evaluated, anatomical alignment was accurate in all cases, and pairwise SULpeak quantification was accurate in 95%. Pairwise SULpeak quantification failed in seven lesion pairs due to proximity to other lesions or misclassified physiological uptake. Review time was less than one minute for most cases. CONCLUSION: This study demonstrates the feasibility of AI-assisted PERCIST evaluation for [18F]FDG PET-CT, showing promising accuracy. coPERCIST offers potential for reproducible response assessment and supports future multicentre validation. It is freely available to researchers via the RECOMIA platform.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Trägårdh E, Larsson M, Enqvist O, et al. coPERCIST: AI-assisted PET-CT response assessment. Eur J Nucl Med Mol Imaging. 2025. PMID: 41120595. doi:10.1007/s00259-025-07614-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。